Project description:Human cancer cell lines (DLD1 wt or ZNF692 KO, and for IP-proteomics HCT116 transfected with GFP, GFP-ZNF692 and deltaNolsZNF692). 788570, HCT116 transfected with GFP;
788571, HCT116 transfected with GFP-ZNF692;
788572, HCT116 transfected with deltaNolsZNF692;
937612, control 40S subunit from DLD1 cells;
937613, control 60S subunit from DLD1 cells;
937614, control 80S monosome fraction from DLD1 cells;
937615, KO ZNF692 40S subunit from DLD1 cells;
937616, KO ZNF692 60S subunit from DLD1 cells;
937617, KO ZNF692 80S monosome fraction from DLD1 cells;
943031, control 40S subunit from DLD1 cells;
943032, control 60S subunit from DLD1 cells;
943033, control 80S monosome fraction from DLD1 cells;
943034, KO ZNF692 40S subunit from DLD1 cells;
943035, KO ZNF692 60S subunit from DLD1 cells;
943036, KO ZNF692 80S monosome fraction from DLD1 cells
Project description:Gene expression between DLD1 and DLD1 derived oxaliplatin resistant clones (DLD/OHP1, DLD/OHP4, and DLD/OHP5) was assessed Gene expression between HCT116 and HCT116 derived oxaliplatin resistant clones (HCT/OHP1, HCT/OHP3, and HCT/OHP5) was assessed
Project description:MicroRNA profiling in colon cancer cell lines. Two cell lines have been found with impairment on the export of precursor miRNAs into the cytoplasm (XPO5), HCT15 and DLD1. To test the microRNAs involved several comparisons have been performed: DLD1 and HCT15 cell lines have been compared with XPO5 wild-type cell lines (HCT116 and RKO). Furthermore the transfected XPO5 wild-type defective cells (DLD1.XPO5 wt and HCT15.XPO5 wt) have been compared respect to the non-transfected cells (HCT15 and DLD1). Finally the cell lines HCT15 and DLD1 transfected with a negative control (HCT15.XPO5 358-366 and DLD1.XPO5 358-366) have been compared with respect to non-transfected cell lines (HCT15 and DLD1).
Project description:Whole transciptome analysis of colon cancer mutated cell lines(HCT116 and DLD1) under serum starvation conditions (19hrs-0.5%FBS) We used microarrays to compare gene regulation of truncated cell lines, knocked-out of either the wild type or mutated allele of PI3K, for two independent colon cancer cell lines
Project description:Cancer stem cells (CSCs) are present in small quantities in tumor populations. To permit various analyses of CSCs, we attempted to enrich and expand ornithine decarboxylase (ODC) degron-transduced colorectal cancer (CRC) cells, which retain low proteasome activity. ZsGreen fluorescence-positive (ZsGreen+) cells were collected by sorting the ODC degron-transduced HCT116, DLD1, and SW480 cells, which were defined as enriched ZsGreen+ cells. ZsGreen+ cells still maintained CSC properties. These cells had higher stem cell marker expression and increased resistance to chemotherapy with 5-fluorouracil and oxaliplatin. ZsGreen+ HCT116 and DLD1 cells had greater sphere-forming ability and enhanced tumorigenicity compared to ZsGreen- control cells. Time-lapse microscopy showed that a single enriched ZsGreen+ HCT116 cell had asymmetric cell division. Thus, model CSCs were acquired in sufficient quantity. Using these cells, we performed a comprehensive microRNA analysis; miR- 491-3p was a candidate to suppress cancer stemness. Finally, we found that up- regulated genes in the enriched HCT116 ZsGreen+ cells correlated with those up- regulated in human clinical spheroid samples established from patient-derived xenografts derived from CRC tissue samples, further supporting the acquisition of enriched model CSCs. These cells would be useful in identifying novel CSC markers and developing medicine for anti-CSC therapy.
